Status:
UNKNOWN
Pituitary Derived-Intermedin is an Estrogen-Modulated Factor for Reducing Blood Pressure
Lead Sponsor:
Chang Gung Memorial Hospital
Conditions:
Menopause
Hypertension
Eligibility:
FEMALE
20-90 years
Brief Summary
Calcitonin, calcitonin gene-related peptides (CGRPs), adrenomedullin, and amylin belong to a unique group of peptide hormones important for the regulation of calcium balance, neurotransmission, cardio...
Detailed Description
Specific Aim: Validation that intermedin represents an estrogen-regulated vasoactive hormone from the pituitary Hypothesis: Intermedin is a mediator of the vaso-regulatory effects of estrogens. Ra...
Eligibility Criteria
Inclusion
- Premenopausal women: no reported change in menstrual cycle pattern
- Early peri-menopausal women: reported change in menstrual cycle frequency in preceding year with a bleed in the preceding 3 months
- Late peri-menopausal women: no menses in the preceding 3-11 months
- Postmenopausal women: no menses in the preceding 12 months
- Patients who received oophorectomy
- Patients who received hysterectomy for benign uterus tumor
- Patients underwent assisted reproductive technology (ART).
Exclusion
- Patients underwent chemotherapy or radiotherapy in past two years
Key Trial Info
Start Date :
May 1 2005
Trial Type :
OBSERVATIONAL
End Date :
May 1 2007
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT00133783
Start Date
May 1 2005
End Date
May 1 2007
Last Update
October 26 2005
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chailin Chang
Kwei-Shan, Tao-Yuan, Taiwan, 333